The Food and Drug Administration (FDA) on June 29 approved Phesgo, a breast cancer treatment that can be administered at home by health care professionals.
Phesgo is a fixed-dose combination of two monoclonal antibodies and it allows treatment for both early and metastatic HER2-positive breast cancer for outpatients. The two monoclonal antibodies are pertuzumab, trastuzumab, and the combination also includes hyaluronidase, a substance that is injected into the patient to increase absorption of the medication. The treatment’s approval was granted to Genentech Inc.